Selenium in oxidation state zero is a potent and selective anti-leukemia/lymphoma agent

被引：0
|
作者：
Sieber, F [1 ]
机构：
[1] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
EXPERIMENTAL HEMATOLOGY | 2003年 / 31卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
178
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [41] Dasatinib-loaded albumin nanoparticles possess diminished endothelial cell barrier disruption and retain potent anti-leukemia cell activity
    Dong, Chunling
    Li, Bo
    Li, Zhenyu
    Shetty, Sreerama
    Fu, Jian
    ONCOTARGET, 2016, 7 (31) : 49699 - 49709
  • [42] Rhodium(II) Proximity-Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Anti-Leukemia Activity
    Minus, Matthew B.
    Liu, Wei
    Vohidov, Farrukh
    Kasembeli, Moses M.
    Long, Xin
    Krueger, Michael J.
    Stevens, Alexandra
    Kolosov, Mikhail I.
    Tweardy, David J.
    Sison, Edward Allan R.
    Redell, Michele S.
    Ball, Zachary T.
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2015, 54 (44) : 13085 - 13089
  • [43] Potent anti-cancer effects of selective GPR132/G2A agonist imipridone ONC212 in leukemia and lymphoma
    Prabhu, Varun Vijay
    Madhukar, Neel
    Tarapore, Rohinton
    Garnett, Mathew
    McDermott, Ultan
    Benes, Cyril
    Charter, Neil
    Deacon, Sean
    Oster, Wolfgang
    Andreeff, Michael
    Elemento, Olivier
    Stogniew, Martin
    Allen, Joshua
    CANCER RESEARCH, 2017, 77
  • [44] 2'-FLUORO-5-IODO-ARACYTOSINE, A POTENT AND SELECTIVE ANTI-HERPESVIRUS AGENT
    LOPEZ, C
    WATANABE, KA
    FOX, JJ
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1980, 17 (05) : 803 - 806
  • [45] Selective expansion of NK receptor-positive anti-leukemia cytotoxic T cells from leukemia patients treated with hematopoietic stem cell transplantation.
    Ogasawara, M
    Ogawa, T
    Imai, K
    Kobayashi, N
    Kiyama, Y
    Higa, T
    Tanaka, J
    Imamura, M
    Kasai, M
    BLOOD, 2002, 100 (11) : 57B - 57B
  • [46] Novel PEG-grafted nanostructured lipid carrier for systematic delivery of a poorly soluble anti-leukemia agent Tamibarotene: characterization and evaluation
    Liu, Xin
    Zhang, Zhihua
    Jiang, Yuqi
    Hu, Yue
    Wang, Zhonglan
    Liu, Junli
    Feng, Ruihua
    Zhang, Jie
    Huang, Guihua
    DRUG DELIVERY, 2015, 22 (02) : 223 - 229
  • [47] Potent anti-leukemia activities of humanized chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphoblast leukemia
    Xiao, Lei
    Zhang, Qing
    Zhu, Xiaofan
    Wu, Zhao
    BONE MARROW TRANSPLANTATION, 2018, 53 : 233 - 233
  • [48] Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia
    Hu, Yongxian
    Wu, Zhao
    Luo, Yi
    Shi, Jimin
    Yu, Jian
    Pu, Chengfei
    Liang, Zuyu
    Wei, Guoqing
    Cui, Qu
    Sun, Jie
    Jiang, Jing
    Xie, Jue
    Tan, Yamin
    Ni, Wanmao
    Tu, Jifang
    Wang, Jinping
    Jin, Aiyun
    Zhang, Hao
    Cai, Zhen
    Xiao, Lei
    Huang, He
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3297 - 3306
  • [49] Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
    Yasuhiko Kano
    Miyuki Akutsu
    Saburo Tsunoda
    Tohru Izumi
    Hiroyuki Kobayashi
    Hiroyuki Mano
    Yusuke Furukawa
    Investigational New Drugs, 2007, 25 : 31 - 40
  • [50] Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines
    Kano, Yasuhiko
    Akutsu, Miyuki
    Tsunoda, Saburo
    Izumi, Tohru
    Kobayashi, Hiroyuki
    Mano, Hiroyuki
    Furukawa, Yusuke
    INVESTIGATIONAL NEW DRUGS, 2007, 25 (01) : 31 - 40
12345